In drug discovery and development, every part of the process matters. Scientists learn from every experiment and every observation. In fact, some of the most cutting-edge advancements in medicine are being dreamed up from findings uncovered in the past. In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble dive deep into antibody drug conjugates, a groundbreaking modality that uses targeted antibody engineering to deliver potent chemotherapy directly to cancer-causing cells. They explore the complex ADC creation process and learn how ADCs are changing the standard of care for bladder cancer, from someone with a personal relationship to the disease. Featured Guests: – Renee Barron-Gores, Caregiver – Phoenix Ho, Vice President, Oncology Early Clinical Development, Pfizer – Sharsti Sandall, Executive Director, ADC Biology, Oncology Research Unit, Pfizer Dive into the episode here: 1:16 - Old ideas yield new discoveries 3:01 - How do antibody drug conjugates work? 5:07 - The origins of ADCs 8:36 - ADCs allow for more targeted cancer treatment 10:44 - How are ADCs structured? 14:16 - How do scientists find the best ADC combinations? 18:27 - Developing oncology drugs 22:02 - ADCs and bladder cancer 24:28 - A caregiver’s perspective on cancer treatment 38:12 - Science Will Win Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios. Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer)

 410      7